Rendement sur 1 an (CAGR)
-2.63%
Sanofi SA Exchange (PA, EUR)
SAN.PA
83.74
+0.43 (+0.51%)
HealthcareDrug Manufacturers - General
Loading...
Rendement sur 3 ans (CAGR)
-0.53%
Rendement sur 5 ans (CAGR)
0.29%
Rendement sur 10 ans (CAGR)
1.01%
Adobe 3e trimestre 2026 – Le sentiment du marché influence-t-il le prix ?
Lire plusCapitalisation boursière
101.27B
Cours/chiffre d'affaires
2.11
Valeur d'entreprise
154.42B
Cours/valeur comptable
1.46
Rendement du div
0.00%
Années de croissance
-
Croissance du div
-
Versement FCF
62.02%
Trailing P/E
14.98
PEG
-
P/E prévisionnel
9.30
Croissance EPS
-8.21%
Informations sur les actions
Qu'est-ce qu'une bourse ? Fonctionnement, acteurs, exemples
Lire plusGraphique boursier
Loading...
Données du prix des actions
| Ouverture | 84.50 |
| Max journalier | 85.37 |
| Min journalier | 83.82 |
| Volume journalier | 3.39M |
| Niveau record | 109.62 |
| Estimation des analystes sur 1 an | 94.06 |
| Beta | 0.28 |
| EPS (TTM) | 5.65 |
| Dividende par action | 0.00 |
| Date ex-div | 5 May 2026 |
| Prochaine date de bénéfices | 23 Apr 2026 |
Potentiel de baisse
Loading...
Données du potentiel de baisse
| SAN.PA | S&P500 | |
| Baisse de prix actuelle par rapport au niveau record | -23.61% | -5.62% |
| Baisse de prix actuelle la plus importante | -55.80% | -56.47% |
| Date de la baisse la plus importante | 10 Oct 2008 | 9 Mar 2009 |
| Baisse moyenne par rapport au record | -19.79% | -10.64% |
| Délai moyen pour nouveau record | 44 days | 12 days |
| Délai max pour nouveau record | 2908 days | 1805 days |
Actualite
Vaxart (OTCMKTS:VXRT) expects to report efficacy and safety data from the main cohort of its Phase 2b COVID-19 vaccine trial by mid-2027, while its current cash runway extends into the second quarter ...
8 novembre 2026
Novavax (NVAX) is back in focus after Q3 2026 results and new detail on its vaccine partnership with Sanofi, including a triggered US$125 million milestone tied to a Phase 3 combination trial. Recent ...
7 novembre 2026
Nurix Therapeutics reported that Sanofi terminated the Phase 1 trial and broader SAR448272 STAT6 degrader program, while Nurix remains eligible for milestones and royalties from other partnered assets...
7 novembre 2026
Novavax shares fall 8% despite Q3 earnings and revenue beat as costs decline, while a Sanofi milestone drives a sharp increase in its 2026 outlook.
6 novembre 2026
Novavax (NASDAQ:NVAX) raised its 2026 revenue framework after partner Sanofi began a late-stage trial of a combination influenza and COVID-19 vaccine in Europe, triggering a $125 million milestone pay...
6 novembre 2026
Novavax Inc (NVAX) raised its 2026 revenue framework by $145 million on a $125 million Sanofi milestone, cut operating expenses 41% year over year, and now expects its cash to last into 2029.
6 novembre 2026
T-Therapeutics will now generate proof-of-concept data for its oncology and immunology TCE drugs with “blockbuster” potential.
5 novembre 2026
Vaccine biotechnology company Novavax (NASDAQ:NVAX) beat Wall Street’s revenue expectations in Q3 2026, but revenue fell by 3% year on year to $68.3 million. The company’s full-year revenue guidance o...
5 novembre 2026
Novavax, Inc. (Nasdaq: NVAX) today announced its financial results and operational highlights for the third quarter ended September 30, 2026.
5 novembre 2026
Sanofi (ENXTPA:SAN) is back in focus after third quarter results and an earnings guidance upgrade for 2026, paired with a strong month-long share move of about 20%. For context, Sanofi’s share price h...
5 novembre 2026